

DAFTAR PUSTAKA

1. Sterling JC. *Human papillomavirus infections*. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. *Fitzpatrick's dermatology in general medicine*. 9th ed. Philadelphia: McGraw-Hill Companies; 2019. p. 3096–104.
2. William, James WD, Berger TG E. Viral disease. In: James WD, Berger, Elston, editors. *Andrews' Diseases of the skin clinical dermatology*. 10th ed. Philadelphia: Saunders Elsevier; 2006. p. 397–401.
3. Jordan Witchev D, Brianne Witchev N, Roth-Kauffman MM, Kevin Kauffman M. Plantar warts: Epidemiology, pathophysiology, and clinical management. *J Am Osteopath Assoc*. 2018;118(2):92–105.
4. Kirnbauer R, Lenz P, Okun MM. *Human papillomavirus*. In: Bologna JL, Jorizza JL, Rapini RP, editors. *Dermatology*. 2nd ed. Spain: Mosby elsevier; 2008. p. 1183–97.
5. Bruggink SC, Eekhof JAH, Egberts PF, Van Blijswijk SCE, Assendelft WJJ, Gussekloo J. Warts transmitted in families and schools: A prospective cohort. *Pediatrics*. 2013;131(5):928–34.
6. Tampi PGI, Mawu FO, Niode NJ. Profil veruka vulgaris di poliklinik kulit dan kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Januari - Desember 2013. *e-CliniC*. 2016;4(1):2–7.
7. Prabawaningrum K, Zulkarnain I. Profil infeksi virus di divisi dermatologi anak unit rawat jalan Kesehatan Kulit dan Kelamin RSUD Dr . Soetomo Surabaya. *BIKKK - Berkala Ilmu Kesehat Kulit dan Kelamin*. 2015;20(1):24–31.
8. Dalimunthe DA, Siregar R, Tanjung C. Lama waktu penyembuhan berkorelasi dengan karakteristik pasien pada pengobatan veruka vulgaris dengan pengolesan larutan fenol 80 %. *BIKKK - Berkala Ilmu Kesehat Kulit dan Kelamin*. 2016;28(1):23–6.
9. Abeck D, Tetsch L, Lüftl M, Biedermann T. Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. *J Ger Soc Dermatology JDDG*. 2019;17(6):613–34.
10. Redzic N, Benoy I, Vanden Broeck D, Bogers JP. Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial. *Contemp Clin Trials Commun*. 2020;17:100534.
11. Mahran AM, Twisy HO, Elghazally SA, Badran AY. Evaluation of different concentrations of hydrogen peroxide solution (3% and 6%) as a potential new therapeutic option of nongenital warts: A randomized controlled triple-blinded clinical trial. *J Cosmet Dermatol*. 2020;19(2):416–22.
12. Kwok C, Gibbs S, Bennett C, Holland R, Abbott R. Topical treatments for cutaneous warts (Review). *Cochrane Database Syst Rev*. 2014;2012(9):180.
13. Sterling JC, Gibbs S, Hussain SSH, Mustapa MFM, Sterling J. *British*

- Association of Dermatologists' guidelines for the management of cutaneous warts 2014. *Br J Dermatol.* 2014;(171):696–712.
14. Widiaty S, Soebono H, Nilasari H, Listiawan MY, Siswati AS, Triwahyudi D, et al. Panduan Praktik Klinis bagi Dokter Spesialis Kulit dan Kelamin di Indonesia. Jakarta: PP PERDOSKI; 2017. 151–154 p.
 15. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. *Br J Dermatol.* 2001;144(1):4–11.
 16. Qamar HY, Batool M, Hanif I. Comparison of efficacy of 40% topical salicylic acid and cryotherapy in patient with palmoplantar warts. *J Med Physiol Biophys.* 2018;43:28–32.
 17. Haroen MS, Purba HM, Kartadjukardi E, Sularsito SA. Giant verruca vulgaris: A case report. *Med J Indones.* 2009;18(2):135–8.
 18. Cockayne S, Hewitt C, Hicks K, Jayakody S, Kang'ombe AR, Stamuli E, et al. Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): A randomised controlled trial. *Bmj.* 2011;342(7811).
 19. Dall'Oglio F, D'Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: An evidence-based review. *Am J Clin Dermatol.* 2012;13(2):73–96.
 20. Tiong WHC, Kelly EJ. Salicylic acid burn induced by wart remover: A report of two cases. *Burns.* 2009;35(1):139–40.
 21. Sulistyaningrum SK, Nilasari H, Effendi EH. Penggunaan asam salisilat dalam dermatologi. *J Indones Med Assoc.* 2012;62(7):277–84.
 22. Chan HP, Maibach HI. Hydrogen peroxide, blanching, and skin: An overview. *Cutan Ocul Toxicol.* 2008;27(4):307–9.
 23. Murphy EC, Friedman AJ. Hydrogen peroxide and cutaneous biology: Translational applications, benefits, and risks. *J Am Acad Dermatol.* 2019;81(6):1379–86.
 24. DuBois JC, Jarratt M, Beger BB, Bradshaw M, Powala C V., Shanler SD. A-101, a proprietary topical formulation of high-concentration hydrogen peroxide solution: A randomized, double-blind, vehicle-controlled, parallel group study of the dose-response profile in subjects with seborrheic keratosis of the face. *Dermatol Surg.* 2018;44(3):330–40.
 25. Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). *J Am Acad Dermatol.* 2018;79(5):869–77.
 26. Balasubramaniam D, Burkhart CG. Hydrogen peroxide use for chemical destruction in seborrheic keratosis: A review. *Open Dermatol J.* 2020;13(1):68–70.
 27. Tyring SK, Smith SR, Gold MH, Bradshaw M, Shanler SD. Patients with common warts: posttreatment results from the phase 2 WART 203 trial. Annual Meeting of the American Academy of Dermatology. Washington DC; 2019.
 28. Jaury DF. Gambaran nilai VAS (Visual Analogue Scale) pasca bedah seksio sesar pada penderita yang diberikan tramadol. *e-CliniC.* 2014;2(1):1–7.

29. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. *Arthritis Care Res.* 2011;63(SUPPL. 11):240–52.
30. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Breivik Hals EK, et al. Assessment of pain. *Br J Anaesth.* 2008;101(1):17–24.
31. Safikhani S, Gries KS, Trudeau JJ, Reasner D, Rüdell K, Coons SJ, et al. Response scale selection in adult pain measures: Results from a literature review. *J Patient-Reported Outcomes.* 2018;2.
32. Abdullah Y, Indra D, Puar N. Skala nyeri. In: Abdullah Y, editor. *Manajemen Nyeri.* 1st ed. Padang: RSUP.DR.M.Djamil Padang; 2015. p. 10–3.
33. Sterling JC. Viral infections. In: Griffith C, Barker J, Barker T, Chalmers R, Creater D, editors. *Rooks Text Book.* 9th ed. United Kingdom: Wiley Blackwell; 2016. p. 25.46.
34. Al-Mutairi N, AlKhalaf M. Mucocutaneous warts in children: Clinical presentations, risk factors, and response to treatment. *Acta Dermatovenerologica.* 2013;21(4):69–72.
35. Bruggink SC, Eekhof JAH, Egberts PF, Van Blijswijk SCE, Assendelft WJJ, Gussekloo J. Warts transmitted in families and schools: A prospective cohort. *Pediatrics.* 2013;131(5):928–34.
36. Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological study of different types of warts. *Dermatol Res Pract.* 2016;2016:1–4.
37. Bacaj P, Burch D. Human papillomavirus infection of the skin. *Arch Pathol Lab Med.* 2018;142(6):700–5.
38. Tyring SK. Human papillomavirus infections: Epidemiology, pathogenesis, and host immune response. *J Am Acad Dermatol.* 2000;43(1 II):18–26.
39. Fera Ibrahim. Virologi human papilloma virus. In: Andrijono, Indriatmi W, editors. *Infeksi human papilloma virus.* Jakarta: Badan Penerbit FKUI; 2013. p. 3–13.
40. Egelkroun. The biology of genital human papillomaviruses. In: Holmes, editor. *sexually transmitted disease.* 4th ed. New york: The McGraw-Hill Companies, Inc; 2008. p. 463–88.
41. Brendle SA, Bywaters SM, Christensen ND. Pathogenesis of infection by human papillomavirus. *Curr Probl Dermatology.* 2014;45(1872):47–57.
42. Aqil N, Nassiri A, Baybay H, Gallouj S, Sara E. Warts under the dermoscope. *SM Dermatology J.* 2019;5(Figure 8):3–6.
43. Zalaudek I. Dermoscopy in general dermatology. In: Marghoob A, Malvey J, Braun RP, editors. *Atlas of dermoscopy.* 2nd ed. United Kingdom: Informa Healthcare; 2012. p. 325–35.
44. Soutor C, Hordinsky M. *Clinical Dermatology.* 1st editio. United States: McGraw-Hill Education, LLC; 2013. 88–94 p.
45. James WD, Berger TG, Elston DM, Neuhaus A. *Andrew’s disease of the skin.* 12th ed. Phikadelphia: Elsevier, Inc.; 2016. 1083 p.
46. Lynch MD, Cliffe J, Morris-Jones R. *Management of cutaneous viral warts.*

- BMJ. 2014;348(May):1–6.
47. Trozak D, Tennenhouse D, Rusel J. Verruca vulgaris. In: Current Clinical Practice: Dermatology Skills for Primary Care: An Illustrated Guide. New Jersey: Humana Press; 2013. p. 59–65.
 48. Bacelieri R, Johnson SM. Cutaneous warts: An evidence-based approach to therapy. *Am Fam Physician*. 2005;72(4):647–52.
 49. Asmara A, Daili SF, Noegrohowati T, Zubaedah I. Vehikulum dalam dermatoterapi topikal. *Media Dermato-Venereologica Indones*. 2012;39(1):25–35.
 50. Kuwabara AM, Rainer BM, Basdag H, Cohen BA. Children with warts: A retrospective study in an outpatient setting. *Pediatr Dermatol*. 2015;32(5):679–83.
 51. Ockenfels HM. Therapeutic management of cutaneous and genital warts. *JDDG - J Ger Soc Dermatology*. 2016;14(9):892–9.
 52. Bruggink S, Gussekloo J, Berger M, Zaaijer K, Assendelft WJJ, Waal MWM De, et al. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: randomized controlled trial. *Can Med Assoc J*. 2010;182(15):1–4.
 53. Soenjoyo KR, Chua B, Wei L, Wee Y, Jean M, Koh A, et al. Treatment of cutaneous viral warts in children : A review. *Dermatol Ther*. 2020;e14034.
 54. Judy Schynder. A-101 45 % topical solution meets primary and all secondary efficacy endpoints in pivotal phase 3 trial for the treatment of common warts (THWART-2). Aclaris Inc. 2020;1–10.
 55. Smith SR, Trying SK, KK Grande KK, Schlessinger J, Gold MH S. Hydrogen peroxide topical solution, 45% for common warts: phase 2 efficacy and safety trial results. *J Drugs Dermatol*. 2020;Oct 01;19(10):969–76.
 56. Rolf-Detlef Treede. The International Association for the Study of Pain. *Pain reports*. 2018;3:e643.
 57. Kane RL, Bershadsky B, Rockwood T, Saleh K, Islam NC. Visual Analog Scale pain reporting was standardized. *J Clin Epidemiol*. 2005;58(6):618–23.
 58. Hjerstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. *J Pain Symptom Manage*. 2011;41(6):1073–93.
 59. Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, et al. Validation of the Wong-Baker FACES pain rating scale in pediatric emergency department patients. *Acad Emerg Med*. 2010;17(1):50–4.
 60. Gopal V, Shenoy MM, Pinto M. Common warts revisited: a clinical study. *Int J Res Dermatology*. 2017;3(2):261.
 61. Dalimunthe DA, Siregar R, Tanjung C. Comparative clinical efficacy between electrodesiccation with curettage and application of 80% phenol solution in treatment of common warts. *Open Access Maced J Med Sci*. 2018;6(2):326–9.
 62. Liu J, Li H, Yang F, Ren Y, Xia T, Zhao Z, et al. Epidemiology and clinical profile of cutaneous warts in Chinese college students : A cross-sectional and follow-up study. *Sci Rep*. 2018;8:1–8.

63. Linley E, Denyer SP, McDonnell G, Simons C, Maillard JY. Use of hydrogen peroxide as a biocide: New consideration of its mechanisms of biocidal action. *J Antimicrob Chemother.* 2012;67(7):1589–96.
64. Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. *Redox Biol.* 2017;11(January):613–9.
65. Sudhakar Rao KM, Ankad BS, Naidu V, Sampaghavi V V, Unni MM, Aruna MS. Electrosurgery VS 40% salicylic acid in the treatment of warts. *J Clin Diagnostic Res.* 2012;6(1):81–4.
66. Salecha AJ, Samanthula H, Shaik FA, Jakkampudi A, Ruvva S. Comparative study of 40% hydrogen peroxide and 50% trichloroacetic acid in the treatment of seborrheic keratoses. *J Pakistan Assoc Dermatologists.* 2020;30(4):656–61.

